PNAS 2011-08-02

High-resolution, noninvasive longitudinal live imaging of immune responses.

Midhat H Abdulreda, Gaetano Faleo, Ruth Damaris Molano, Maite Lopez-Cabezas, Judith Molina, Yaohong Tan, Oscar A Ron Echeverria, Elsie Zahr-Akrawi, Rayner Rodriguez-Diaz, Patrick K Edlund, Ingo Leibiger, Allison L Bayer, Victor Perez, Camillo Ricordi, Alejandro Caicedo, Antonello Pileggi, Per-Olof Berggren

Index: Proc. Natl. Acad. Sci. U. S. A. 108(31) , 12863-8, (2011)

Full Text: HTML

Abstract

Intravital imaging emerged as an indispensible tool in biological research, and a variety of imaging techniques have been developed to noninvasively monitor tissues in vivo. However, most of the current techniques lack the resolution to study events at the single-cell level. Although intravital multiphoton microscopy has addressed this limitation, the need for repeated noninvasive access to the same tissue in longitudinal in vivo studies remains largely unmet. We now report on a previously unexplored approach to study immune responses after transplantation of pancreatic islets into the anterior chamber of the mouse eye. This approach enabled (i) longitudinal, noninvasive imaging of transplanted tissues in vivo; (ii) in vivo cytolabeling to assess cellular phenotype and viability in situ; (iii) local intervention by topical application or intraocular injection; and (iv) real-time tracking of infiltrating immune cells in the target tissue.


Related Compounds

Related Articles:

Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model.

2011-07-01

[Transpl. Immunol. 25(1) , 49-55, (2011)]

Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.

2010-12-01

[J. Acquir. Immune Defic. Syndr. 55(4) , 420-7, (2010)]

Synthesis of [19, 35, 36-(13)C(3)]-labeled TAK779 as a molecular probe.

2009-08-15

[Bioorg. Med. Chem. 17(16) , 5769-74, (2009)]

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.

2012-01-01

[J. Virol. 86(2) , 1119-28, (2012)]

C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.

2010-12-01

[J. Gen. Virol. 91(Pt 12) , 2965-73, (2010)]

More Articles...